{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:12:20Z","timestamp":1788844340790,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018998","name":"Ege University Research Foundation","doi-asserted-by":"publisher","award":["Project Number: 30810"],"award-info":[{"award-number":["Project Number: 30810"]}],"id":[{"id":"10.13039\/501100018998","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04938-1","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:56:02Z","timestamp":1788843362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Birinapant enhances cisplatin sensitivity in epithelial ovarian cancer through modulation of apoptotic and survival signaling pathways"],"prefix":"10.1007","volume":"96","author":[{"given":"Elham","family":"Shahnazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rostamlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aras","family":"Gezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-3237","authenticated-orcid":false,"given":"Cumhur","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"5","key":"4938_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ (2024) Global epidemiology of epithelial ovarian cancer. Nat Reviews Clin Oncol 21(5):389\u2013400","journal-title":"Nat Reviews Clin Oncol"},{"issue":"2","key":"4938_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/cancers14020416","volume":"14","author":"M K\u00f6bel","year":"2022","unstructured":"K\u00f6bel M, Kang EY (2022) The Evolution of Ovarian Carcinoma Subclassification. Cancers 14(2):416","journal-title":"Cancers"},{"issue":"10","key":"4938_CR3","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.3390\/ijms26104611","volume":"26","author":"B Smolarz","year":"2025","unstructured":"Smolarz B et al (2025) Ovarian Cancer\u2014Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors\u2019 Molecular Backgrounds. Int J Mol Sci 26(10):4611","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4938_CR4","first-page":"497429","volume":"2010","author":"K Ushijima","year":"2010","unstructured":"Ushijima K (2010) Treatment for Recurrent Ovarian Cancer\u2014At First Relapse. J Oncol 2010(1):497429","journal-title":"J Oncol"},{"issue":"2","key":"4938_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/ijgc-2018-000067","volume":"29","author":"RD Morgan","year":"2019","unstructured":"Morgan RD et al (2019) Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer. Int J Gynecol Cancer 29(2):341\u2013345","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"4938_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.drup.2009.09.001","volume":"12","author":"MMK Shahzad","year":"2009","unstructured":"Shahzad MMK, Lopez-Berestein G, Sood AK (2009) Novel strategies for reversing platinum resistance. Drug Resist Updates 12(6):148\u2013152","journal-title":"Drug Resist Updates"},{"issue":"7338","key":"4938_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nature09852","volume":"471","author":"A Oberst","year":"2011","unstructured":"Oberst A et al (2011) Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471(7338):363\u2013367","journal-title":"Nature"},{"key":"4938_CR8","doi-asserted-by":"crossref","unstructured":"Uzunparmak B et al (2020) Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic\u2013induced necroptosis. JCI Insight, 5(23)","DOI":"10.1172\/jci.insight.139837"},{"issue":"5","key":"4938_CR9","first-page":"646","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Robert A, Weinberg (2011) Hallmarks Cancer: Next Generation Cell 144(5):646\u2013674","journal-title":"Hallmarks Cancer: Next Generation Cell"},{"issue":"12","key":"4938_CR10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10495-017-1429-4","volume":"22","author":"MS Mohamed","year":"2017","unstructured":"Mohamed MS et al (2017) Inhibitors of apoptosis: clinical implications in cancer. Apoptosis 22(12):1487\u20131509","journal-title":"Apoptosis"},{"issue":"1","key":"4938_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0092-8674(00)00008-8","volume":"102","author":"C Du","year":"2000","unstructured":"Du C et al (2000) Smac, a Mitochondrial Protein that Promotes Cytochrome c\u2013Dependent Caspase Activation by Eliminating IAP Inhibition. Cell 102(1):33\u201342","journal-title":"Cell"},{"key":"4938_CR12","doi-asserted-by":"publisher","first-page":"1562167","DOI":"10.3389\/fphar.2025.1562167","volume":"16","author":"Q Ye","year":"2025","unstructured":"Ye Q et al (2025) Targeting the inhibitors of apoptosis proteins (IAPs) to combat drug resistance in cancers. Front Pharmacol 16:1562167","journal-title":"Front Pharmacol"},{"issue":"7","key":"4938_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","volume":"22","author":"R Rathore","year":"2017","unstructured":"Rathore R et al (2017) Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 22(7):898\u2013919","journal-title":"Apoptosis"},{"issue":"9","key":"4938_CR14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s10495-007-0087-3","volume":"12","author":"AM Hunter","year":"2007","unstructured":"Hunter AM, LaCasse EC, Korneluk RG (2007) The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12(9):1543\u20131568","journal-title":"Apoptosis"},{"key":"4938_CR15","doi-asserted-by":"crossref","unstructured":"Fulda S (2017) Chapter Four - Smac Mimetics to Therapeutically Target IAP Proteins in Cancer, in International Review of Cell and Molecular Biology, L. Galluzzi, Editor. Academic Press. pp. 157\u2013169","DOI":"10.1016\/bs.ircmb.2016.09.004"},{"issue":"4","key":"4938_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1158\/1535-7163.MCT-13-0798","volume":"13","author":"CA Benetatos","year":"2014","unstructured":"Benetatos CA et al (2014) Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-\u03baB Activation, and Is Active in Patient-Derived Xenograft Models. Mol Cancer Ther 13(4):867\u2013879","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"4938_CR17","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1021\/jm500176w","volume":"57","author":"SM Condon","year":"2014","unstructured":"Condon SM et al (2014) Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies. J Med Chem 57(9):3666\u20133677","journal-title":"J Med Chem"},{"issue":"1","key":"4938_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12935-014-0075-y","volume":"14","author":"E Sagher","year":"2014","unstructured":"Sagher E et al (2014) The small molecule NSC676914A is cytotoxic and differentially affects NF\u03baB signaling in ovarian cancer cells and HEK293 cells. Cancer Cell Int 14(1):75","journal-title":"Cancer Cell Int"},{"issue":"2","key":"4938_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clon.2006.11.013","volume":"19","author":"RO Esc\u00e1rcega","year":"2007","unstructured":"Esc\u00e1rcega RO et al (2007) The Transcription Factor Nuclear Factor-kappa B and Cancer. Clin Oncol 19(2):154\u2013161","journal-title":"Clin Oncol"},{"issue":"Pt 4","key":"4938_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1242\/jcs.075770","volume":"124","author":"JY Kim","year":"2011","unstructured":"Kim JY et al (2011) TNF\u03b1 induced noncanonical NF-\u03baB activation is attenuated by RIP1 through stabilization of TRAF2. J Cell Sci 124(Pt 4):647\u2013656","journal-title":"J Cell Sci"},{"issue":"2","key":"4938_CR21","first-page":"745","volume":"34","author":"B Piura","year":"2014","unstructured":"Piura B et al (2014) Distinct expression and localization of TNF system in ovarian carcinoma tissues: possible involvement of TNF-\u03b1 in morphological changes of ovarian cancerous cells. Anticancer Res 34(2):745\u2013752","journal-title":"Anticancer Res"},{"issue":"4","key":"4938_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2007.10.037","volume":"131","author":"JE Vince","year":"2007","unstructured":"Vince JE, Wong WW, Khan N, Feltham R, Chau D (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131(4):682\u2013693","journal-title":"Cell"},{"issue":"48","key":"4938_CR23","doi-asserted-by":"publisher","first-page":"6252","DOI":"10.1038\/onc.2008.302","volume":"27","author":"EC LaCasse","year":"2008","unstructured":"LaCasse EC et al (2008) IAP-targeted therapies for cancer. Oncogene 27(48):6252\u20136275","journal-title":"Oncogene"},{"key":"4938_CR24","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2147\/OTT.S33375","volume":"9","author":"L Dubrez","year":"2013","unstructured":"Dubrez L, Berthelet J, Glorian V (2013) IAP proteins as targets for drug development in oncology. Onco Targets Ther 9:1285\u20131304","journal-title":"Onco Targets Ther"},{"issue":"12","key":"4938_CR25","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.3390\/cancers12123784","volume":"12","author":"AM Noonan","year":"2020","unstructured":"Noonan AM et al (2020) Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer. Cancers 12(12):3784","journal-title":"Cancers"},{"issue":"22","key":"4938_CR26","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-15-0365","volume":"21","author":"S Fulda","year":"2015","unstructured":"Fulda S (2015) Promises and Challenges of Smac Mimetics as Cancer Therapeutics. Clin Cancer Res 21(22):5030\u20135036","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4938_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41419-024-06631-8","volume":"15","author":"RS Dmello","year":"2024","unstructured":"Dmello RS et al (2024) Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer. Cell Death Dis 15(4):255","journal-title":"Cell Death Dis"},{"issue":"3","key":"4938_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/ijo.2022.5325","volume":"60","author":"T Singh","year":"2022","unstructured":"Singh T et al (2022) Efficacy of birinapant in combination with carboplatin in targeting platinum\u2013resistant epithelial ovarian cancers. Int J Oncol 60(3):35","journal-title":"Int J Oncol"},{"issue":"9","key":"4938_CR29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745\u2013756","journal-title":"Nat Rev Immunol"},{"issue":"36","key":"4938_CR30","doi-asserted-by":"publisher","first-page":"24295","DOI":"10.1074\/jbc.C800128200","volume":"283","author":"E Varfolomeev","year":"2008","unstructured":"Varfolomeev E et al (2008) c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor \u03b1 (TNF\u03b1)-induced NF-\u03baB Activation*. J Biol Chem 283(36):24295\u201324299","journal-title":"J Biol Chem"},{"issue":"33","key":"4938_CR31","doi-asserted-by":"publisher","first-page":"11778","DOI":"10.1073\/pnas.0711122105","volume":"105","author":"DJ Mahoney","year":"2008","unstructured":"Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, Korneluk RG (2008) Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 105(33):11778\u201311783","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4938_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13046-018-0703-9","volume":"37","author":"BX Li","year":"2018","unstructured":"Li BX et al (2018) Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway. J Exp Clin Cancer Res 37(1):53","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"4938_CR33","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/cancers15041315","volume":"15","author":"Y Shibuya","year":"2023","unstructured":"Shibuya Y et al (2023) SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-\u03b1 Autocrine Signaling. Cancers 15(4):1315","journal-title":"Cancers"},{"issue":"12Supplement","key":"4938_CR34","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1158\/1538-7445.AM2022-1068","volume":"82","author":"BT Wang","year":"2022","unstructured":"Wang BT et al (2022) Abstract 1068: Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity. Cancer Res 82(12Supplement):1068\u20131068","journal-title":"Cancer Res"},{"issue":"5","key":"4938_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ccr.2007.08.029","volume":"12","author":"SL Petersen","year":"2007","unstructured":"Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, Wang X (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5):445\u2013456","journal-title":"Cancer Cell"},{"key":"4938_CR36","doi-asserted-by":"publisher","first-page":"1124912","DOI":"10.3389\/fonc.2022.1124912","volume":"12","author":"S Prasopporn","year":"2023","unstructured":"Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S (2023) Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Front Oncol 12:1124912","journal-title":"Front Oncol"},{"issue":"10","key":"4938_CR37","doi-asserted-by":"publisher","first-page":"e1496","DOI":"10.1038\/cddis.2014.448","volume":"5","author":"KE McCabe","year":"2014","unstructured":"McCabe KE et al (2014) Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma. Cell Death Dis 5(10):e1496\u2013e1496","journal-title":"Cell Death Dis"},{"issue":"26","key":"4938_CR38","doi-asserted-by":"publisher","first-page":"11936","DOI":"10.1073\/pnas.1005667107","volume":"107","author":"SL Petersen","year":"2010","unstructured":"Petersen SL, Peyton M, Minna JD, Wang X (2010) Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci USA 107(26):11936\u201311941","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4938_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41420-021-00511-2","volume":"7","author":"LF Hernandez","year":"2021","unstructured":"Hernandez LF et al (2021) Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism. Cell Death Discov 7(1):134","journal-title":"Cell Death Discov"},{"issue":"11","key":"4938_CR40","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1158\/1535-7163.MCT-15-0475","volume":"14","author":"RK Amaravadi","year":"2015","unstructured":"Amaravadi RK et al (2015) A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Mol Cancer Ther 14(11):2569\u20132575","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"4938_CR41","doi-asserted-by":"publisher","first-page":"8393","DOI":"10.3390\/ijms26178393","volume":"26","author":"LdC Braga","year":"2025","unstructured":"Braga LdC et al (2025) The OvarianTag\u2122 Biomarker Panel Emerges as a Prognostic Tool to Guide Clinical Decisions in Cisplatin-Based Treatment of Epithelial Ovarian Cancer. Int J Mol Sci 26(17):8393","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4938_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/cancers16010107","volume":"16","author":"K Gasimli","year":"2024","unstructured":"Gasimli K et al (2024) Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors. Cancers 16(1):107","journal-title":"Cancers"},{"key":"4938_CR43","first-page":"1539","volume":"6","author":"L He","year":"2013","unstructured":"He L et al (2013) Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. Onco Targets Ther 6:1539\u20131543","journal-title":"Onco Targets Ther"},{"issue":"9","key":"4938_CR44","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41401-019-0340-7","volume":"41","author":"XL Zheng","year":"2020","unstructured":"Zheng XL et al (2020) RIP1 promotes proliferation through G2\/M checkpoint progression and mediates cisplatin-induced apoptosis and necroptosis in human ovarian cancer cells. Acta Pharmacol Sin 41(9):1223\u20131233","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"4938_CR45","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486\u2013541","journal-title":"Cell Death Differ"},{"issue":"2","key":"4938_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrm.2016.149","volume":"18","author":"R Weinlich","year":"2017","unstructured":"Weinlich R, Oberst A, Beere HM, Green DR (2017) Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol 18(2):127\u2013136. https:\/\/doi.org\/10.1038\/nrm.2016.149","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"19","key":"4938_CR47","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1158\/0008-5472.CAN-19-3850","volume":"80","author":"AC Palmer","year":"2020","unstructured":"Palmer AC et al (2020) A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts. Cancer Res 80(19):4278\u20134287","journal-title":"Cancer Res"},{"key":"4938_CR48","doi-asserted-by":"crossref","unstructured":"Psilopatis I et al (2022) Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing. Biomedicines, 11(1)","DOI":"10.3390\/biomedicines11010001"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04938-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04938-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04938-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:56:04Z","timestamp":1788843364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04938-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4938"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04938-1","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"97"}}